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Autosomal recessive congenital ichthyosis type 1 (ARCI1), a clinically heterogeneous group of keratini-
zation disorders, develops due to mutations in the transglutaminase 1 (TGM1) gene. Here we report a
Hungarian pedigree affected by the lamellar ichthyosis clinical form of the ARCI1 phenotype. Direct
sequencing revealed two recurrent heterozygous mutations: a splice site (c.877-2A > G) and a missense
(c.1135G > C, p.Val379Leu) mutation. This splice site mutation is the most frequently observed in ARCI1
worldwide. The missense mutation is relatively rare and has been reported in only 13 Scandinavian
patients. Comparison of the clinical phenotypes of our Hungarian patients and the Scandinavian patients
demonstrates great phenotypic diversity associated with the p.Val379Leu genotype.
Copyright © 2017, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Autosomal recessive congenital ichthyosis (ARCI) is a clinically and
genetically heterogenic group of rare monogenic diseases charac-
terized by abnormal skin scaling over the whole body.1 The main
skin phenotypes are lamellar ichthyosis and congenital ichthyosi-
form erythroderma, although phenotypic overlap in the same pa-
tient or in patients of the same family can occur.1
ARCI type 1 (ARCI1, OMIM 242300) is a common form of ARCI
caused by mutations in the transglutaminase 1 (TGM1, OMIM
190195) gene on chromosome 14q12.2 The TGM1 gene encodes
transglutaminase 1 (TGM1), which is responsible for crosslinking
epidermal proteins during formation of the stratum corneum.2
TGM1 mutations have been linked to several clinical variants of
ARCI1, such as the well-known lamellar ichthyosis phenotype3 and
the self-healing collodion baby phenotype, in which the condition
is present at birth but spontaneously improves.4 A very rare form of
this latter clinical variant is the acral self-healing collodion baby, in
which the membrane is located on the extremities only.5 TGM1interest to declare.
etics, University of Szeged, 4
y).
al Association. Published by Elseviemutations can also lead to development of the bathing suit ich-
thyosis, another clinical form of ARCI1, in which scaling is pro-
nounced on the bathing suit area and is less pronounced on the
extremities.6
In this study, we report a Hungarian family with two members
affected by ARCI1. Our genetic investigation identiﬁed that these
members carried two recurrent heterozygous mutations in a
compound heterozygous state.
Case report
A Hungarian family with two affected siblings was investigated.
The affected individuals were 18 (Patient II/1) and 13 (Patient II/3)
years old at the time of investigation. Patient II/1 had dark brown
thick scales on her chest (Fig. 1a) and back (Fig. 1b). Her elbows and
knees (Fig. 1c) and her ﬂexural regions (Fig. 1d) were affected. The
back of her hands were also covered by thick scales (Fig. 1e), but her
palms (Fig. 1f) and soles were unaffected. Patient II/3, whose
symptoms were milder than Patient II/1, had light brown thick
scales covering his chest (Fig. 1g) and back (Fig. 1h). His elbows and
knees (Fig. 1i) and his ﬂexural regions (Fig. 1j) were also affected.
The back of his hands were also scaly (Fig. 1k), but his palms (Fig. 1l)
and soles were unaffected. Ectropion was present in both patients,
whereas alopecia was not observed. Both Patients II/1 and II/3 werer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1 Clinical symptoms of the affected patients and pedigree of the Hungarian family. Squares and circles denote males and females; ﬁlled symbols indicate clinically affected
family members.
A. Sulak et al. / Dermatologica Sinica 36 (2018) 89e9290bornwith a collodionmembrane encasing their bodies. The parents
(I/1 and I/2) and the third sibling (II/2) were clinically unaffected by
ARCI1 (Fig. 1m).
The patients have been treated with the repeated course of
isotretinoin, which could reduce scaling successfully. Besides sys-
temic treatments, the patients are continuously using topical
creams both with keratolytic agents such as urea, lactic acid or
salicylic acid and both with moisturizers. The treatments can
reduce the symptoms of the patients, but if the treatments are
stopped the symptoms are coming back, therefore they need reg-
ular dermatological care.
We aimed to identify the disease-causing mutation of the TGM1
gene in this Hungarian family. For genetic investigation, peripheral
blood samples were taken from the affected patients and their
clinically unaffected family members as well as from unrelated,
healthy Hungarian individuals (n ¼ 30), and genomic DNA was
isolated using a BioRobot EZ1 DSP Workstation (QIAGEN; Godollo,
Hungary). The coding regions and the ﬂanking introns of the TGM1
gene were ampliﬁed and sequenced (primer sequences used were
taken from the UCSC Genome Browser www.genome.ucsc.edu).
The investigationwas approved by the Internal Review Board of the
University of Szeged, Szeged, Hungary. Written informed consent
was obtained all the investigated subjects. The study was con-
ducted according to the Principles of the Declaration of Helsinki.
Direct sequencing of the coding regions and the ﬂanking introns
of the TGM1 gene revealed two heterozygous mutations, one splice
site mutation (c.877-2A > G) 50 of the sixth exon and one missense
mutation (c.1135G > C p.Val379Leu) in the seventh exon. Both
affected siblings (II/1 and II/3) carried thesemutations, suggesting a
compound heterozygous state. The patients' mother (I/2) carried
the splice site mutation and the patients' father (I/1) carried the
missense mutation. The clinically unaffected sibling (II/2) carried
the paternal missense mutation in heterozygous form, but did not
carry the maternal splice site mutation (Fig. 1m). These results
suggest that the splice site mutation is of maternal origin and the
missense mutation is of paternal origin. All the unrelated healthy
Hungarian controls (n ¼ 30) carried the wild type sequence.Discussion
The investigated two Hungarian ARCI1 patients carried two recur-
rent mutations of the TGM1 gene: a missense mutation
(p.Val379Leu) and a splice site mutation (c.877-2A > G). Both
mutations were located in the catalytic core domain of the TGM1
enzyme. Previous functional studies have demonstrated that mu-
tations affecting this domain might severely diminish TGM1 ac-
tivity due to the less stable structure of the catalytic core.7 Others
proved that the domain lowers the speciﬁc activity of the TGM1
protein due to misfolding or by resulting in an excessively stable
protein that cannot be processed.8 Mutations of the catalytic core
domain mainly cause the development of the lamellar ichthyosis
phenotype of ARCI1, but some of mutations, including p.Arg264Gln,
p.Arg264TRp, p.Tyr276Asn, p.Arg307Gly, p.Arg315Cys and
p.Arg315His, have been linked with the bathing suit ichthyosis
phenotype.6 Note, arginine is the most frequently mutated amino
acid in TGM1, possibly due to methyl-induced deamination of CpG
dinucleotides.9
The splice sitemutation (c.877-2A>G) can lead to the formation
of two different splice variants, both of which result in a premature
stop codon.10 One variant results in an insertion of a G before
nucleotide c.877T.11 The other causes the inclusion of intron 5 in
between exon 5 and 6 in transcribed mRNA.12 This mutation has
been reported in approximately 28% of ARCI1 patients, making it
the most common TGM1 gene mutation reported worldwide, and
affects Caucasian Americans, African-Americans, Germans, Nor-
wegians and Egyptians.9,13 This mutation probably originated in
Northern Germany (Westphalia) and later spread worldwide with
immigration.10 However, our investigated Hungarian family was
not aware of any German ancestry; although, the family name
suggests Bulgarian origin.
The p.Val379Leu missense mutation has only been reported
previously in 13 ARCI1 patients of Scandinavian origin.12,14,15 None
of these patients carried this mutation in a homozygous form
(Table 1). In 12 cases of the total 15 patients (including the Hun-
garian individuals), a compound heterozygous state for two
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A. Sulak et al. / Dermatologica Sinica 36 (2018) 89e92 91missense mutations were present.12,14,15 Of these mutations,
p.Val379Leu was most frequently (n ¼ 7 patients, 58%) associated
with the p.Arg143Cys mutation and was reported in Finnish pa-
tients.14 In two Swedish patients, the p.Val379Leu was combined
with the p.Ser358Arg mutation.12 The combinations of the
p.Val379Leu mutation with p.Arg142His, p.Arg396Leu and
p.Asp430Val were detected only once in Finnish and Norwegian
patients.14,15 The investigated Hungarian family was not aware of
any Scandinavian ancestry. It would be interesting to use haplotype
analysis to investigate whether the same mutation (p.Val379Leu)
carried by the Scandinavian and the Hungarian patients is the result
of the same founder event or it is the consequence of independent
mutation events.
The detailed comparison of the clinical symptoms of the re-
ported 15 ARCI1 patients who all carry the p.Val379Leu mutation
give further insight into the genotypeephenotype correlations of
this mutation (Table 1). Regarding the skin symptoms, the majority
of these patients clearly show the typical lamellar ichthyosis
phenotype with brown, thick scales (n ¼ 9, 60%); however, four of
them developed thin, whitish scales.12,14,15 The most common
symptom associated with the p.Val379Leu-phenotype is the pres-
ence of ectropion and the degree of severity on ﬂexural areas,
which were present in nearly all of the patients (n ¼ 14, 93%).12,14,15
The palms and soles are also frequently affected, detected in 80% of
the patients (n ¼ 12).12,14,15 Alopecia was present only in one third
of the patients (n ¼ 5, 33%), all of whom are Finnish.7 It is inter-
esting to note that the knees and elbows were affected only in our
Hungarian patients (n ¼ 2, 13%). Regarding the skin at birth, in 13
cases (86%) the patients were born with collodion membrane
encasing their body.14,15 Two patients showed ichthyosiform
erythroderma at birth. One of these patients (P13) subsequently
developed lamellar ichthyosis phenotype at the age of two years.15
The observed differences in the clinical symptoms of the 15 ARCI
patients carrying the heterozygous p.Val379Leu missense mutation
clearly demonstrate the wide phenotypic diversity and the variable
expressivity of the disease. In general, ectropion and the affected-
ness of the ﬂexural areas and unaffectedness of the palms and soles
are the hallmarks of this phenotype. Further studies are needed to
identify putative genetic, environmental or lifestyle factors, which
might be responsible for the observed wide phenotypic diversity.
The availability of the extended clinical ﬁndings for the carriers of
the p.Val379Leumutatione as provided by this studye is critical for
promoting our understanding of the disease andmight enhance the
development of causative new therapeutic modalities for ARCI1
patients. One recent example for this attempt is the development of
the enzyme-replacement therapy for individuals suffering from
TGM1-deﬁcient ARCI1.16 It has been used successfully in a mouse
model for the restoration of the TGM1 activity and for the rear-
rangement of the epidermal integrity and thus barrier function.16
This approach is a promising putative modality for the treatment
of this extremely stigmatizing disease and hopefully more effective
than the current symptomatic therapies available forARCI1patients.Acknowledgements
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